vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($346.7M vs $339.0M, roughly 1.0× HAEMONETICS CORP). Dolby Laboratories, Inc. runs the higher net margin — 15.4% vs 13.2%, a 2.2% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -2.9%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $50.2M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -2.5%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DLB vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $346.7M | $339.0M |
| Net Profit | $53.3M | $44.7M |
| Gross Margin | 87.5% | 59.7% |
| Operating Margin | 17.9% | 19.9% |
| Net Margin | 15.4% | 13.2% |
| Revenue YoY | -2.9% | -2.7% |
| Net Profit YoY | -21.4% | 19.3% |
| EPS (diluted) | $0.55 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $346.7M | $339.0M | ||
| Q3 25 | $307.0M | $327.3M | ||
| Q2 25 | $315.5M | $321.4M | ||
| Q1 25 | $369.6M | $330.6M | ||
| Q4 24 | $357.0M | $348.5M | ||
| Q3 24 | $304.8M | $345.5M | ||
| Q2 24 | $288.8M | $336.2M | ||
| Q1 24 | $364.5M | — |
| Q4 25 | $53.3M | $44.7M | ||
| Q3 25 | $49.3M | $38.7M | ||
| Q2 25 | $46.1M | $34.0M | ||
| Q1 25 | $91.8M | $58.0M | ||
| Q4 24 | $67.8M | $37.5M | ||
| Q3 24 | $58.6M | $33.8M | ||
| Q2 24 | $38.4M | $38.4M | ||
| Q1 24 | $97.8M | — |
| Q4 25 | 87.5% | 59.7% | ||
| Q3 25 | 87.1% | 59.5% | ||
| Q2 25 | 86.1% | 59.8% | ||
| Q1 25 | 90.3% | 58.4% | ||
| Q4 24 | 88.6% | 55.5% | ||
| Q3 24 | 88.8% | 54.2% | ||
| Q2 24 | 87.7% | 52.0% | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 17.9% | 19.9% | ||
| Q3 25 | 9.7% | 17.9% | ||
| Q2 25 | 15.1% | 16.8% | ||
| Q1 25 | 29.2% | 21.6% | ||
| Q4 24 | 22.4% | 16.9% | ||
| Q3 24 | 15.2% | 15.0% | ||
| Q2 24 | 12.7% | 11.8% | ||
| Q1 24 | 29.9% | — |
| Q4 25 | 15.4% | 13.2% | ||
| Q3 25 | 16.1% | 11.8% | ||
| Q2 25 | 14.6% | 10.6% | ||
| Q1 25 | 24.8% | 17.5% | ||
| Q4 24 | 19.0% | 10.8% | ||
| Q3 24 | 19.2% | 9.8% | ||
| Q2 24 | 13.3% | 11.4% | ||
| Q1 24 | 26.8% | — |
| Q4 25 | $0.55 | $0.95 | ||
| Q3 25 | $0.50 | $0.81 | ||
| Q2 25 | $0.48 | $0.70 | ||
| Q1 25 | $0.94 | $1.17 | ||
| Q4 24 | $0.70 | $0.74 | ||
| Q3 24 | $0.59 | $0.66 | ||
| Q2 24 | $0.40 | $0.74 | ||
| Q1 24 | $1.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $644.6M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $2.6B | $911.5M |
| Total Assets | $3.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $644.6M | $363.4M | ||
| Q3 25 | $702.6M | $296.4M | ||
| Q2 25 | $699.3M | $292.9M | ||
| Q1 25 | $626.6M | $306.8M | ||
| Q4 24 | $520.8M | $320.8M | ||
| Q3 24 | $482.0M | $299.3M | ||
| Q2 24 | $869.0M | $344.4M | ||
| Q1 24 | $825.4M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.6B | $911.5M | ||
| Q3 25 | $2.6B | $849.2M | ||
| Q2 25 | $2.6B | $882.3M | ||
| Q1 25 | $2.6B | $820.8M | ||
| Q4 24 | $2.5B | $906.9M | ||
| Q3 24 | $2.5B | $878.9M | ||
| Q2 24 | $2.4B | $905.4M | ||
| Q1 24 | $2.4B | — |
| Q4 25 | $3.2B | $2.5B | ||
| Q3 25 | $3.2B | $2.4B | ||
| Q2 25 | $3.2B | $2.5B | ||
| Q1 25 | $3.2B | $2.5B | ||
| Q4 24 | $3.2B | $2.5B | ||
| Q3 24 | $3.1B | $2.5B | ||
| Q2 24 | $3.0B | $2.5B | ||
| Q1 24 | $3.0B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $54.8M | $93.6M |
| Free Cash FlowOCF − Capex | $50.2M | $87.2M |
| FCF MarginFCF / Revenue | 14.5% | 25.7% |
| Capex IntensityCapex / Revenue | 1.3% | 1.9% |
| Cash ConversionOCF / Net Profit | 1.03× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $715.3M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.8M | $93.6M | ||
| Q3 25 | $472.2M | $111.3M | ||
| Q2 25 | $67.7M | $17.4M | ||
| Q1 25 | $174.9M | $116.6M | ||
| Q4 24 | $106.8M | $43.8M | ||
| Q3 24 | $327.3M | $48.8M | ||
| Q2 24 | $21.3M | $-27.4M | ||
| Q1 24 | $181.4M | — |
| Q4 25 | $50.2M | $87.2M | ||
| Q3 25 | $435.9M | $106.3M | ||
| Q2 25 | $61.3M | $13.6M | ||
| Q1 25 | $168.0M | $100.9M | ||
| Q4 24 | $100.0M | $35.2M | ||
| Q3 24 | $297.2M | $39.4M | ||
| Q2 24 | $13.7M | $-33.1M | ||
| Q1 24 | $172.5M | — |
| Q4 25 | 14.5% | 25.7% | ||
| Q3 25 | 142.0% | 32.5% | ||
| Q2 25 | 19.4% | 4.2% | ||
| Q1 25 | 45.5% | 30.5% | ||
| Q4 24 | 28.0% | 10.1% | ||
| Q3 24 | 97.5% | 11.4% | ||
| Q2 24 | 4.7% | -9.8% | ||
| Q1 24 | 47.3% | — |
| Q4 25 | 1.3% | 1.9% | ||
| Q3 25 | 11.8% | 1.5% | ||
| Q2 25 | 2.0% | 1.2% | ||
| Q1 25 | 1.9% | 4.7% | ||
| Q4 24 | 1.9% | 2.5% | ||
| Q3 24 | 9.8% | 2.7% | ||
| Q2 24 | 2.6% | 1.7% | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 1.03× | 2.09× | ||
| Q3 25 | 9.57× | 2.88× | ||
| Q2 25 | 1.47× | 0.51× | ||
| Q1 25 | 1.91× | 2.01× | ||
| Q4 24 | 1.57× | 1.17× | ||
| Q3 24 | 5.59× | 1.44× | ||
| Q2 24 | 0.55× | -0.71× | ||
| Q1 24 | 1.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing Brodcast Revenue | $100.3M | 29% |
| Licensing Mobile Revenue | $74.9M | 22% |
| Licensing Other Revenue | $70.2M | 20% |
| Licensing CE Revenue | $45.6M | 13% |
| Licensing PC Revenue | $28.7M | 8% |
| Products And Services | $26.9M | 8% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
